TELUS Health is monitoring close to 4,000 drugs in the pipeline today, of which just under 1,000 are in the latest stage of development (phase III) and not quite 300 are awaiting final regulatory approval in some jurisdictions, including Canada. The top five therapeutic classes for these drugs are as follows: Oncology (cancer) Central nervous system (i.e., for neurological and mental health disorders) Infectious disease Hormonal system (e.g., drugs for diabetes) Immune system Higher-cost specialty drugs dominate the pipeline for oncology and the immune system, and are present throughout the remaining categories (particularly for infectious diseases). In many cases, these specialty drugs deliver breakthrough therapies for the target patient populations; in some cases, the drugs offer first-ever treatments for patients who currently struggle to cope with the symptoms of their disease. This article summarizes which of the upcoming therapies are…
To read this article you must be logged in
We will use your email address to send you our newsletter. All communications will be from TELUS Health.
We will use your email address to send you our newsletter.
All communications will be from TELUS Health.
All fields are required